

# Association of Polygenic Score and the involvement of Cholinergic and Glutamatergic Pathways with Lithium Treatment Response in Patients with Bipolar Disorder

**Azmeraw Amare** (✉ [azmeraw.amare@adelaide.edu.au](mailto:azmeraw.amare@adelaide.edu.au))

University of Adelaide, AUSTRALIA <https://orcid.org/0000-0002-7940-0335>

**Anbupalam Thalamuthu**

University of New South Wales

**Klaus Oliver Schubert**

University of Adelaide <https://orcid.org/0000-0003-1690-0209>

**Janice Fullerton**

Neuroscience Research Australia <https://orcid.org/0000-0003-4014-4490>

**Muktar Ahmed**

**Simon Hartmann**

**Sergi Papiol**

University Hospital LMU <https://orcid.org/0000-0001-9366-8728>

**Urs Heilbronner**

University Hospital, LMU Munich <https://orcid.org/0000-0001-7135-762X>

**Franziska Degenhardt**

University of Bonn

**Fasil Tekola-Ayele**

**Liping Hou**

National Institute of Mental Health

**Yi-Hsiang Hsu**

**Tatyana Shekhtman**

University of California San Diego

**Mazda Adli**

Charité - Universitätsmedizin Berlin, Campus Charité Mitte

**Nirmala Akula**

**Kazufumi Akiyama**

Dokkyo Medical University School of Medicine

**Raffaella Ardau**

Hospital University Agency of Cagliari

**Bárbara Arias**

Facultat de Biologia and Institut de Biomedicina (IBUB), Universitat de Barcelona, CIBERSAM

**Jean-Michel Aubry**

Geneva University Hospitals

**Lena Backlund**

**Abesh Kumar Bhattacharjee**

University of California San Diego

**Frank Bellivier**

Pôle de Psychiatrie, AP-HP, Groupe Hospitalier Lariboisière-F. Widal

**Antoni Benabarre**

Hospital Clinic of Barcelona

**Susanne Bengesser**

Medical University of Graz

**Joanna Biernacka**

Mayo Clinic <https://orcid.org/0000-0001-9350-4440>

**Armin Bimer**

Medical University of Graz

**Cynthia Marie-Claire**

INSERM UMR-S 1144 <https://orcid.org/0000-0002-2282-134X>

**Pablo Cervantes**

McGill University Health Centre

**Hsi-Chung Chen**

National Taiwan University Hospital <https://orcid.org/0000-0003-3191-0093>

**Caterina Chillotti**

**Sven Cichon**

Research Center Juelich <https://orcid.org/0000-0002-9475-086X>

**Cristiana Cruceanu**

Max Plank Institute for Psychiatry <https://orcid.org/0000-0002-7799-5531>

**Piotr Czerski**

Poznan University of Medical Sciences <https://orcid.org/0000-0003-0745-5916>

**Nina Dalkner**

Medical University of Graz

**Maria Del Zompo**

University of Cagliari <https://orcid.org/0000-0001-9491-5938>

**J. Raymond DePaulo**

Johns Hopkins University

**Bruno Etain**

InsERM U955, Psychiatry Genetics <https://orcid.org/0000-0002-5377-1488>

**Stéphane Jamain**

Univ Paris Est Creteil, INSERM, IMRB <https://orcid.org/0000-0002-4321-4100>

**Peter Falkai**

University Hospital LMU

**Andreas J. Forstner**

University of Bonn, School of Medicine & University Hospital Bonn <https://orcid.org/0000-0002-1876-6368>

**Louise Frisé**

Karolinska Institutet and Center for Molecular Medicine, Karolinska University Hospital

**Mark Frye**

Mayo Clinic <https://orcid.org/0000-0001-6997-4215>

**Sébastien Gard**

Hôpital Charles Perrens

**Julie Garnham**

<https://orcid.org/0000-0002-7987-4995>

**Fernando Goes**

fgoes1@jhmi.edu <https://orcid.org/0000-0001-6262-8264>

**Maria Grigoriu-Serbanescu**

Alexandru Obregia Clinical Psychiatric Hospital <https://orcid.org/0000-0002-1304-6687>

**Andreas Fallgatter**

University of Tuebingen

**Sophia Stegmaier**

University of Tuebingen

**Thomas Ethofer**

University Hospital Tübingen

**Silvia Biere**

University Hospital Tübingen

**Kristiyana Petrova**

University Hospital Tübingen

**Ceylan Schuster**

University Hospital Tübingen

**Kristina Adorjan****Monika Budde**

Ludwig Maximilian University of Munich

**Maria Heilbronner**

University Hospital Tübingen

**Janos Kalman**

Ludwig Maximilians Universität München <https://orcid.org/0000-0003-0930-4214>

**Mojtaba Oraki Kohshour**

Ludwig Maximilians Universität München

**Daniela Reich-Erkelenz**

Klinikum der Universität München

**Sabrina Schaupp**

University Hospital Tübingen

**Eva Schulte**

University Hospital, LMU Munich <https://orcid.org/0000-0003-3105-5672>

**Fanny Senner**

Klinikum der Universität München

**Thomas Vogl**

University Hospital Tübingen

**Ion-George Anghelescu**

**Volker Arolt**

**Udo Dannlowski**

**Detlef E. Dietrich**

**Christian Figge**

**Markus Jäger**

**Fabian Lang**

**Georg Juckel**

Ruhr University Bochum

**Carsten Spitzer**

**Jens Reimer**

**Max Schmauß**

**Andrea Schmitt**

Ludwig-Maximilians-University (LMU) Munich

**Carsten Konrad**

**Martin von Hagen**

**Jens Wiltfang**

Universitätsmedizin Göttingen <https://orcid.org/0000-0003-1492-5330>

**Jörg Zimmermann**

**Till Andlauer**

Technical University of Munich, Klinikum rechts der Isar <https://orcid.org/0000-0002-2917-5889>

**Andre Fischer**

University of Goettingen, Germany

**Felix BERPohl**

Berlin School of Mind & Brain

**Vivien Kraft**

**Silke Matura**

Goethe University Frankfurt/M.

**Anna Gryaznova**

**Irina Falkenberg**

**Cüneyt Yildiz**

**Tilo Kircher**

**Julia Schmidt**

**Marius Koch**

**Katrin Gade**

**Sarah Trost**

**Ida Haußleiter**

**Martin Lambert**

**Anja C. Rohenkohl**

**Vivien Kraft**

University Medical Center Hamburg-Eppendorf <https://orcid.org/0000-0002-5815-1026>

**Paul Grof**

McGill University

**Ryota Hashimoto**

**Joanna Hauser**

<https://orcid.org/0000-0002-6621-3493>

**Stefan Herms**

**Per Hoffmann**

Institute of Human Genetics

**Esther Jiménez**

**Jean-Pierre Kahn**

**Layla Kassem**

**Po-Hsiu kuo**

College of Public Health, National Taiwan University, Taipei, Taiwan <https://orcid.org/0000-0003-0365-3587>

**Tadafumi Kato**

**John Kelsoe**

**Sarah Kittel-Schneider**

University Hospital of Würzburg <https://orcid.org/0000-0003-3057-6150>

**Ewa Ferensztajn-Rochowiak**

**Barbara König**

Landeskrankenhaus Neunkirchen

**Ichiro Kusumi**

Hokkaido University Graduate School of Medicine <https://orcid.org/0000-0002-8747-5070>

**Gonzalo Laje**

**Mikael Landén**

Gothenburg University <https://orcid.org/0000-0002-4496-6451>

**Catharina Lavebratt**

Karolinska Institutet <https://orcid.org/0000-0003-4987-2718>

**Marion Leboyer**

<https://orcid.org/0000-0001-5473-3697>

**Susan G. Leckband**

VA San Diego Healthcare System

**Alfonso Tortorella**

University of Naples SUN, University of Perugia <https://orcid.org/0000-0002-8095-2305>

**Mirko Manchia**

**Lina Martinsson**

**Michael McCarthy**

VA San Diego Healthcare System <https://orcid.org/0000-0001-6219-4945>

**Susan L. McElroy**

Lindner Center of Hope / University of Cincinnati

**Francesc Colom**

Institut Hospital del Mar d'Investigacions Mèdiques

**Marina Mitjans**

Max Planck Institute of Experimental Medicine, Göttingen, Germany

**Francis Mondimore**

Johns Hopkins University

**Palmiero Monteleone**

University of Salerno

**Caroline Nievergelt**

**Markus Nöthen**

School of Medicine & University Hospital Bonn <https://orcid.org/0000-0002-8770-2464>

**Tomas Novak**

<https://orcid.org/0000-0001-9156-9654>

**Claire O'Donovan**

Dalhousie University

**Norio Ozaki**

University of Salerno

**Andrea Pfennig**

University Hospital Carl Gustav Carus, TU Dresden

**Claudia Pisanu**

University of Cagliari <https://orcid.org/0000-0002-9151-4319>

**James Potash**

**Andreas Reif**

University Hospital Frankfurt, Germany <https://orcid.org/0000-0002-0992-634X>

**Eva Reininghaus**

<https://orcid.org/0000-0001-5964-4087>

**Guy Rouleau**

McGill University <https://orcid.org/0000-0001-8403-1418>

**Janusz K. Rybakowski**

Poznan University of Medical Sciences

**Martin Schalling**

Karolinska Institutet <https://orcid.org/0000-0001-5011-2922>

**Peter Schofield**

Neuroscience Research Australia <https://orcid.org/0000-0003-2967-9662>

**Barbara W. Schweizer**

Johns Hopkins University

**Giovanni Severino**

University of Cagliari <https://orcid.org/0000-0002-6354-2662>

**Paul D Shilling**

University of Salerno

**Kazutaka Shimoda**

<https://orcid.org/0000-0002-9663-6243>

**Christian Simhandl****Claire Slaney****Alessio Squassina**

Università degli Studi Di Cagliari <https://orcid.org/0000-0001-7415-7607>

**Thomas Stamm**

Charité - Universitätsmedizin Berlin, Campus Charité Mitte

**Pavla Stopkova**

National Institute of Mental Health <https://orcid.org/0000-0003-2712-3652>

**Mario Maj**

University of Campania "Luigi Vanvitelli", Naples

**Gustavo Turecki**

McGill University <https://orcid.org/0000-0003-4075-2736>

**Eduard Vieta**

Hospital Clinic of Barcelona <https://orcid.org/0000-0002-0548-0053>

**Julia Veeh**

University Hospital Frankfurt

**Stephanie Witt**

University Medical Centre Mannheim <https://orcid.org/0000-0002-1571-1468>

**Adam Wright**

University of New South Wales

**Peter Zandi**

Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine

<https://orcid.org/0000-0001-8423-2623>

**Philip Mitchell****Michael Bauer****Martin Alda**

Dalhousie University <https://orcid.org/0000-0001-9544-3944>

**Marcella Rietschel**

University of Mannheim <https://orcid.org/0000-0002-5236-6149>

**Francis McMahon**

National Institute of Mental Health Intramural Research Program; National Institutes of Health  
<https://orcid.org/0000-0002-9469-305X>

**Thomas G. Schulze**

Ludwig-Maximilians-University Munich

**Vincent Millischer**

Mayo Clinic <https://orcid.org/0000-0003-1919-9649>

**Scott Clark**

University of Adelaide <https://orcid.org/0000-0003-1640-5611>

**Bernhard Baune**

The University of Munster


---

**Article**

**Keywords:**

**Posted Date:** February 14th, 2023

**DOI:** <https://doi.org/10.21203/rs.3.rs-2580252/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.  
[Read Full License](#)

---



# Abstract

Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li+PGS) in patients with BD. To gain further insights into lithium's possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priors, Li+PGS was developed in the International Consortium of Lithium Genetics cohort (ConLi+Gen: N=2,367) and replicated in the combined PsyCourse (N=89) and BipoLife (N=102) studies. The associations of Li+PGS and lithium treatment response – defined in a continuous ALDA scale and a categorical outcome (good response vs. poor response) were tested using regression models, each adjusted for the covariates: age, sex, and the first four genetic principal components. Statistical significance was determined at  $P < 0.05$ . Li+PGS was positively associated with lithium treatment response in the ConLi+Gen cohort, in both the categorical ( $P=9.8 \times 10^{-12}$ ,  $R^2=1.9\%$ ) and continuous ( $P=6.4 \times 10^{-9}$ ,  $R^2=2.6\%$ ) outcomes. Compared to bipolar patients in the 1st decile of the risk distribution, individuals in the 10th decile had 3.47-fold (95%CI: 2.22-5.47) higher odds of responding favorably to lithium. The results were replicated in the independent cohorts for the categorical treatment outcome ( $P=3.9 \times 10^{-4}$ ,  $R^2=0.9\%$ ), but not for the continuous outcome ( $P=0.13$ ). Gene-based analyses revealed 36 candidate genes that are enriched in biological pathways controlled by glutamate and acetylcholine. Li+PGS may be useful in the development of pharmacogenomic testing strategies by enabling a classification of bipolar patients according to their response to treatment. Keywords: Polygenic score, pharmacogenomics, lithium, bipolar disorder, psychiatry

## Introduction

Bipolar disorder (BD) is a severe and often disabling mental health disorder that affects more than 1% of the population worldwide and is characterized by recurrent episodes of depression and mania <sup>1</sup>. BD accounted for 9.3 million disability-adjusted life years (DALYs) in 2017, and imposes a significant social and economic burden on society and healthcare systems <sup>2,3</sup>. BD is associated with a significant somatic and psychiatric comorbidity <sup>1</sup> and an increased risk of suicide <sup>4</sup>.

Since the discovery of lithium's mood-stabilizing property in 1949 <sup>5</sup>, it has been widely used as a first-line therapy for patients with BD <sup>6,7</sup>. Lithium is effective in treating acute episodes of illness and reduces the risk of future recurrences of mania and depression <sup>8</sup>. It has also been shown to reduce the risk of suicide <sup>9</sup>. Despite these merits, the efficacy of lithium is highly variable, with about 30% of treated patients showing a favorable response while more than 30% of them have no clinical response at all <sup>8,10</sup>. Thus far, the causes and predictors of such heterogeneity in treatment response are insufficiently understood.

Genetic factors are thought to contribute, at least in part, to the large interindividual differences in response to lithium<sup>10–15</sup>. So far, only a few genetic studies have identified specific single nucleotide polymorphisms (SNPs) and candidate genes associated with patients' response to lithium or treatment-related side effects<sup>10,11,13–16</sup>. Each employing a genome-wide association study (GWAS) approach, the Taiwan Bipolar Consortium found SNPs in the introns of *GADL1* associated with lithium treatment response<sup>17</sup>, whereas the International Consortium on Lithium Genetics (ConLi<sup>+</sup>Gen) identified a locus on chromosome 21<sup>10</sup>, and a follow-up analysis uncovered additional variants within the human leukocyte antigen (HLA) region<sup>14,16</sup>. Gene expression analysis of ConLi<sup>+</sup>Gen data also showed overexpression of genes involved in mitochondrial functioning in lithium responder patients, highlighting the electron transport chain as a potential target of lithium<sup>18</sup>.

In our recent work, we applied a polygenic score (PGS) modeling approach and demonstrated associations between a poor response to lithium and a high genetic loading for schizophrenia (SCZ)<sup>14</sup>, major depression (MD)<sup>13</sup>, and a meta-PGS combining both SCZ and MD<sup>15</sup>. Machine-learning models that combined clinical variables with the PGS of SCZ and MD has further improved the prediction of lithium treatment response, explaining 13.7% of the variance<sup>19</sup>.

Based on these previous results, translation of PGS testing into clinical practice requires the consideration of three important learnings. First, the PGS of a single phenotype (e.g., SCZ or MD) explains only a small proportion (< 2%) of the variability to treatment response in patients with BD<sup>13,14</sup>, providing insufficient power for clinical use. Second, a meta-PGS from multiple related phenotypes has better predictive power than a PGS from a single phenotype<sup>15</sup>, suggesting the need to explore additional biological markers, including additional PGSs, that can either independently or together with existing PGSs better predict lithium treatment response. Third, developing polygenic markers with *direct* pharmacogenomic implications is essential, for example, a PGS for lithium treatment response (Li<sup>+</sup> PGS), which is perhaps biologically more related to lithium's pharmacological actions than PGSs built for other clinical phenotypes (i.e. SCZ or MD; that may indirectly influence treatment response or symptom severity, but do not index pharmacogenetic signatures *per se*).

Here, we developed a novel Li<sup>+</sup> PGS for lithium treatment response and applied gene-based pathway analyses to identify molecular mechanisms impacted by genetic variation in response phenotypes. Findings may assist in optimizing and personalizing the selection of mood stabilizers in patients with BD, and may point to novel molecular targets for future drug development.

## Methods And Materials

**Study Samples:** For this study, we obtained genetic and clinical data from the International Consortium on Lithium Genetics (ConLi<sup>+</sup>Gen: N = 2,367), Pathomechanisms and Signature in the Longitudinal Course of Psychosis study (PsyCourse: N = 89), and BipolarLife cohort (N = 102). Figure 1 shows the detailed steps of data analysis.

Insert Fig. 1

## Discovery cohort

*ConLi<sup>+</sup>Gen* is a global collaboration of scientists established to study the pharmacogenomics of lithium treatment in patients with BD <sup>10</sup>. In the current study, we analyzed the genome-wide genotype and clinical data of 2,367 lithium-treated bipolar patients of European ancestry collected by 22 participating sites in 13 countries, including Australia (n = 122), Austria (n = 43), Czech Republic (n = 45), France (n = 210), Germany (n = 218), Italy (n = 255), Poland (n = 97), Romania (n = 152), Spain (n = 74), Sweden (n = 304), Switzerland (n = 57), Canada (n = 353) and the USA (n = 437) <sup>10,20</sup>.

## Replication cohort

To replicate Li<sup>+</sup> <sub>PGS</sub> associations found in the discovery ConLi<sup>+</sup>Gen sample, we utilized datasets from PsyCourse and BipoLife where the study participants were of European ancestry. *PsyCourse* is a longitudinal multicenter study conducted from 2012 to 2019 in Germany and Austria, with up to four assessments at 6 monthly intervals. The study comprises 1,320 patients from psychotic-to-affective spectrum, of which, datasets from 89 patients with BD who received lithium treatment were obtained for this study<sup>21</sup>. *BipoLife* is a multicenter cohort study, established to investigate the biological basis of BD and patients' response to treatment and being conducted across ten university hospitals in Germany (Berlin, Bochum, Dresden, Frankfurt, Göttingen, Hamburg, Heidelberg, Marburg, Munich and Tübingen) and the medical informatics section of the University of Göttingen <sup>22</sup>.

## Target outcome

In both discovery and replication cohorts, patient's treatment response was assessed using the "Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder" scale, also called the ALDA scale <sup>10</sup>. The target outcome "lithium treatment response" was defined in categorical and continuous scales among patients who had received lithium for a minimum of 6 months <sup>10</sup>. The detailed procedures of ALDA scale measurement and its validity are described elsewhere <sup>13,14,20</sup>. Briefly, the ALDA scale measures symptom improvement over the course of treatment (A-score, range 0 – 10), which is then weighted against five criteria (B-score that assesses confounding factors, each scored 0, 1, or 2). Once we calculated the total score as 'A-score minus B-score and setting negative scores to zero', the categorical (good versus poor) lithium treatment response was defined at a cut-off score of 7, where patients with a total score of 7 or higher were considered as "responders" <sup>10</sup>. The continuous outcome for lithium treatment response was defined on subscale-A, but patients with a total B score greater than 4 or who had missing data on the totals of ALDA subscale-A or B were excluded <sup>10</sup>.

## Genotyping, Quality Control And Imputation

We obtained the genotype data assayed with different types of commercial SNP arrays across multiple cohorts<sup>10, 21, 22</sup> and applied a series of quality control (QC) procedures before and after imputation using PLINK<sup>23</sup>. First, SNPs that had a poor genotyping rate (< 95%), strand ambiguity (A/T and C/G SNPs), a minor allele frequency (MAF) less than 1% or showed deviation from Hardy-Weinberg Equilibrium ( $P < 10^{-6}$ ) were removed. Then, individuals with low genotype rates (< 95%), who had sex inconsistencies (between the documented and genotype-derived sex), and who were genetically related were excluded.

**Imputation:** The genotype data passing QC were imputed on the Michigan server<sup>24,24</sup> (<https://imputationserver.sph.umich.edu>) separately for each genotyping platform, using the Haplotype Reference Consortium (HRC) reference panel that consists of the largest available set (64,976 human haplotypes) of broadly European haplotypes at 39,235,157 SNPs<sup>25</sup>. For each cohort, imputation quality procedures were implemented to exclude SNPs of low-frequency (MAF < 10%) and low-quality (imputation quality score R-square < 0.6). From the imputed dosage score, genotype calls for the filtered SNPs were derived and common sets of 4,652,947 SNPs across the cohorts were merged using PLINK<sup>23</sup>.

## STATISTICAL ANALYSIS

We implemented polygenic score modeling, genome-wide SNP association, gene-based and functional analysis as described below.

**Genome-wide SNP association analysis:** Genome-wide SNP association analyses were performed on the binary lithium treatment response and continuous ALDA total score using logistic and linear regression models as implemented in PLINK software<sup>23</sup>, respectively. Each analysis was adjusted for the covariates: age, sex, chip type and the first four genetic principal components (PCs).

### Polygenic score development

Using a polygenic score model constructed via Bayesian regression framework and continuous shrinkage (CS) prior on SNP effect sizes implemented in the PRS-CS software<sup>26</sup>, we built  $Li^+_{PGS}$  for individuals of European descent who participated in the ConLi<sup>+</sup>Gen study and replicated the findings in the combined PsyCourse and BipoLife datasets. Polygenic scores were computed using PRS-CS to infer posterior SNP effect sizes under continuous shrinkage (CS) using GWAS summary statistics and an external linkage disequilibrium (LD) reference panel. For the current analysis, the precomputed LD pattern of the 1000 Genomes European reference panel<sup>27</sup> and the discovery GWAS summary statistics were used to calculate PGS scores.

For the ConLi<sup>+</sup>Gen study,  $Li^+_{PGS}$  was derived only for the European ancestry individuals ( $n = 2,367$ ) using a five-fold leave-one-group out (LOG) procedure<sup>28</sup> to remove discovery-target circularity. In each fold, 80% of the sample ( $n = 1,893$ ) was used to generate GWAS summary statistics that were used as discovery for PGS calculation in the 20% left-out target sample ( $n = 474$ ). The procedure was repeated five times by selecting a non-overlapping set of 20% left-out samples to calculate PGS for the entire cohort. Finally,  $Li^+$

$P_{GS}$  was computed for the PsyCourse and BipolarLife participants using ConLi+Gen's GWAS summary statistics (discovery sample) generated from the full European cohort ( $n = 2,367$ ).

**Polygenic score association analysis:** To assess the association of  $Li^+_{PGS}$  with lithium treatment response, a binary logistic regression model was applied for the binary outcome (good versus poor response to lithium treatment), and a Tobit analysis model (censored regression) was used for the continuous outcome (*ALDA total*)<sup>29</sup>. In addition, we divided the ConLiGen sample into deciles, ranging from the lowest polygenic load (1st decile, reference group) to the highest polygenic load (10th decile). Then, we compared BD patients in the higher polygenic load deciles (2nd – 10th deciles) with patients in the lowest polygenic load decile (1st decile). In both the binary and continuous outcomes, the proportion of phenotypic variance explained by  $Li^+_{PGS}$  was computed as the difference in  $R^2$  of the model fit with  $Li^+_{PGS}$  plus covariates, compared to the model fit with only covariates. Each modeling analysis was adjusted for the covariates: age, sex, and the first four genetic PCs, and statistical significance was set at  $p < 0.05$ .

### Gene-based and functional analysis

The gene-based analysis was based on summary statistics generated from the full European ancestry ( $n = 2,367$ ) ConLi+Gen genome-wide SNP association analysis (see Fig. 3) and employed MAGMA (Multi-marker Analysis of GenoMic Annotation)<sup>30</sup>, a tool that uses a multiple regression approach to incorporate LD between markers and to detect multi-marker effects.

To explore the biological context of the genes discovered from the gene-based analysis, a pathway analysis was implemented using PANTHER (Protein ANalysis THrough Evolutionary Relationships; <http://pantherdb.org/>) classification system. PANTHER is designed to classify proteins (and their genes) into biological pathways<sup>31</sup>. To prepare the input genes for PANTHER, we selected genes that showed gene-level association with lithium treatment response (either with the categorical or continuous outcome) at MAGMA adjusted  $p$ -value  $< 0.001$ . This list of genes was entered into PANTHER version-17 which compares the proportion of input genes mapping to a biological pathway to the reference gene list from its databases. Molecular relationships previously experimentally observed in *Homo sapiens* (human) were included. The significance of the overrepresented PANTHER pathways was determined using Fisher's exact test and later adjusted for multiple testing using the Bonferroni correction method. Significant associations were defined at  $p$ -value  $< 0.05$ .

## Results

### Sample Characteristics

The discovery analysis consisted of ConLi+Gen data obtained from 2,367 bipolar patients of European ancestry who had undergone lithium treatment for at least six months. The mean (sd) age of the patients was 47.5(13.9) years and 1,369 (57.8%) were female. In all, 660 (27.9%) of patients had a good response

to lithium treatment (ALDA score  $\geq 7$ ). The mean (sd) ALDA score for ConLi<sup>+</sup>Gen participants was 4.1 (3.1). The replication analysis was based on a combination of the PsyCourse and BipoliLife datasets (N = 191), whose mean (sd) age was 49.1(13.0) years. Of the 191 patients with BD, 48(25.1%) had a good response to lithium (Table 1).

Table 1  
The characteristics of patients with BD and lithium treatment outcomes.

Characteristics BD patients	ConLi <sup>+</sup> Gen	PsyCourse and BipoliLife combined
N = 2,558	N = 2,367	N = 191
Good responders to lithium defined as ALDA total score $\geq 7$ , N (%)	660 (27.9%)	48 (25.1%)
Mean (se) total ALDA score	4.12 (3.15)	4.3 (2.9)
<i>Country of origin</i>	N (%)	
Australia	122 (5.2)	
Austria	43 (1.8)	
Canada	353 (14.9)	
Czech Republic	45 (1.9)	
France	210 (8.9)	
German	218 (9.2)	191 (100%)
Italy	255 (10.8)	
Poland	97 (4.1)	
Romania	152 (6.4)	
Spain	74 (3.1)	
Sweden	304 (12.8)	
Switzerland	57 (2.4)	
USA	437 (18.5)	
Age at interview, mean (sd)	47.5 (13.9)	49.1 (13.0)
Sex, Women, N (%)	1369 (57.8)	84 (44.0%)
BD: Bipolar disorder; N: number, sd: standard deviation; se: standard error.		

## Associations Of Li With Lithium Treatment Response In Bipolar Patients

Using ConLi<sup>+</sup>Gen data, we found statistically significant associations between Li<sup>+</sup><sub>PGS</sub> and lithium treatment response – both in the categorical ( $P = 9.8 \times 10^{-12}$ ,  $R^2 = 1.9\%$ ) and continuous ( $P = 6.4 \times 10^{-9}$ ,  $R^2 = 2.6\%$ ) outcomes. Li<sup>+</sup><sub>PGS</sub> was positively associated with response to lithium treatment, with an adjusted odds ratio (OR) [95%CI] of **1.39** [1.26, 1.54]. In other words, BD patients who carry a higher genetic loading for lithium responsive genetic variants, measured using the Li<sup>+</sup><sub>PGS</sub>, have higher odds of favorable lithium treatment response, compared to patients carrying a low Li<sup>+</sup><sub>PGS</sub> load. Table 2 shows the association results of Li<sup>+</sup><sub>PGS</sub> and lithium treatment response in categorical and continuous outcomes. The odds of a favorable treatment response increased as the Li<sup>+</sup><sub>PGS</sub> increased, ranging from 1.59 fold [95%CI: 1.02–2.49] at the 2nd decile to 3.47 fold [95%CI: 2.22–5.47] at 10th decile, compared to the reference Li<sup>+</sup><sub>PGS</sub> at the 1st decile (Table 2). While there was an increasing trend in the odds of lithium treatment response across the deciles, the most significant prediction contrast was found at the ‘extremes’ (1st and 10th decile) which comprised of ~ 20% of the total cohort (Fig. 2). A replication PGS analysis in the combined PsyCourse and BipoLife samples found a statistically significant association of Li<sup>+</sup><sub>PGS</sub> with the categorical lithium treatment response ( $P = 3.9 \times 10^{-4}$ ,  $R^2 = 0.9\%$ ), but not with the continuous outcome ( $P = 0.13$ ).

Table 2

The association of PGS for lithium variants and treatment response to lithium in patients with BD at different sample splits.

Sample split	N	Categorical outcome		Continuous outcome: ALDA total score, OR (95%CI)	
		OR (95%CI)		unadjusted	adjusted <sup>¥</sup>
ConLi <sup>+</sup> Gen	2367	unadjusted	adjusted	unadjusted	adjusted <sup>¥</sup>
80%/20%	2083/284	1.31(1.19,1.43)	1.39(1.26, 1.54) <sup>¥</sup>	1.15(1.11, 1.20)	1.17(1.13, 1.22)
Li <sup>+</sup> PGS by decile	§R/N				
First (lowest score)	44/236	1[Reference]	1[Reference] <sup>¥</sup>	1[Reference]	1[Reference]
Second	60/237	1.48(0.96, 2.30)	1.59(1.02, 2.49)	0.94(0.79,1.12)	0.96(0.81,1.15)
Third	54/237	1.29(0.82, 2.02)	1.32(0.84, 2.08)	1.07(0.90,1.28)	1.14(0.95,1.35)
Fourth	70/237	1.83(1.19, 2.83)	1.87(1.21, 2.91)	1.09(0.92,1.31)	1.14(0.96,1.36)
Fifth	59/236	1.45(0.94, 2.27)	1.50(0.96, 2.35)	1.12(0.93,1.34)	1.17(0.98,1.40)
Sixth	62/237	1.55(1.00, 2.40)	1.83(1.17, 2.87)	1.22(1.02,1.46)	1.31(1.09,1.55)
Seventh	76/237	2.06(1.35, 3.17)	2.27(1.48, 3.53)	1.15(0.96,1.38)	1.23(1.04,1.48)
Eighth	68/237	1.76(1.14, 2.72)	1.91(1.23, 2.99)	1.12(0.93,1.34)	1.17(0.98,1.39)
Nineth	78/237	2.14(1.41, 3.29)	2.33(1.51, 3.64)	1.45(1.21,1.72)	1.55(1.31,1.86)
Tenth (highest score)	89/236	2.64(1.74, 4.05)	3.47(2.22, 5.47)	1.52(1.27,1.82)	1.67(1.39,1.99)
<b>Legend:</b> The reference decile (1st decile) is the PGS category with the lowest polygenic load for lithium variants. OR (95%CI) for the continuous outcome: ALDA total score is calculated as the exponent of beta coefficient from the linear regression model.					
§R/N: number of lithium responders versus total in that decile; <sup>¥</sup> adjusted for age, sex and 4-genetic principal components, OR: odds ratio.					

Insert Table 2 here

Insert Fig. 2 here



## Genome-wide association, gene-based and functional analysis

After re-imputing the ConLi<sup>+</sup>Gen data in reference to the latest HRC genomes, we conducted GWASs on lithium response, both in categorical and continuous outcomes. This GWAS analysis identified a single locus with lead SNP rs9396756 located near the stathmin domain containing 1 (*STMND1*) gene that reached genome-wide significance for association with the categorical outcome ( $P = 2.7 \times 10^{-8}$ ) and showed a suggestive association with the continuous ALDA score ( $P = 7.6 \times 10^{-8}$ ) (Fig. 3). A follow-up gene-based analysis of the newly derived ConLi<sup>+</sup>Gen GWAS summary statistics found 36 candidate genes likely associated with lithium treatment response – assessed in either continuous or categorical outcomes ( $P < 0.001$ ). In silico functional analysis of the 36 genes revealed enriched biological pathways including the muscarinic acetylcholine receptors 1 and 3 (P-value corrected for multiple testing = 0.026) and metabotropic glutamate receptor group III pathway ( $P = 0.043$ ). These genes and pathways may have an impact on clinical response to lithium treatment and be potential molecular targets for lithium (Supplementary Fig. 1 and Supplementary Table 1).

*Insert Fig. 3 here*

Insert Supplementary Fig. 1 here

## Discussion

This study presents findings from a comprehensive analysis of genetic and clinical data on lithium treatment response that involved the development of a polygenic score for lithium treatment response ( $\text{Li}^+_{\text{PGS}}$ ), genome-wide SNP association and gene-based and functional analyses.

Since the publication of the first GWAS report by the ConLi<sup>+</sup>Gen team<sup>10</sup>, two landmark studies that independently showed the negative association of PGSs for SCZ and MD with lithium treatment response have been published<sup>13–15</sup>. The first study found that 10% of bipolar patients with the lowest polygenic load for SCZ were 3.46 times more responsive to lithium compared to 10% of patients with the highest genetic load for SCZ<sup>14,15</sup>. Similarly, in the second study, 10% of patients who had the lowest genetic loading for MD were 1.54 times more responsive to lithium than 10% of patients with the highest genetic loading for MD<sup>13,15</sup>. Nevertheless, each of these PGSs accounts for < 2% of the total variance to lithium treatment response<sup>13</sup>, suggesting the need to explore additional biological traits that can either independently, or in concert with existing PGSs better predict lithium response. Moreover, the previous PGSs for SCZ and MD are difficult to interpret in a pharmacogenomic context, making the development of a specific lithium response PGS necessary, which is assumed to be more likely to be associated with lithium treatment response and perhaps is biologically more related to lithium's pharmacological actions.

In this novel study, we constructed a PGS for lithium response- $\text{Li}^+_{\text{PGS}}$ , a biological marker of direct pharmacogenomic relevance, and showed a positive relationship between a high genetic loading for lithium treatment response variants and long-term therapeutic response to lithium in patients with BD. We

demonstrated that bipolar patients at the extreme tail end of the distribution have the strongest association, i.e. 10% of patients who carry high genetic loading for lithium responsive variants (10th decile) were 3.47 times more likely to respond to lithium compared to 10% of those with the lowest  $\text{Li}^+_{\text{PGS}}$  (1st decile). These results indicated that  $\text{Li}^+_{\text{PGS}}$  has the potential to help stratify bipolar patients according to predicted lithium response.

In a GWAS of lithium treatment response, we identified a locus near the *STMND1* gene, which encodes for proteins known to be involved in neuron projection development, and active in neuron junctions and cytoplasm. Previous analysis that employed the 1000 Genomes Project reference panel for imputation reported a suggestive association between genetic variants within the *STMND1* gene and lithium treatment response<sup>10</sup>.

Using our newly derived Con $\text{Li}^+$ Gen GWASs summary statistics as an input, we then carried out a gene-based analysis where several genetic variations were examined together for their association with lithium treatment response<sup>30</sup>. This approach found 36 potential target genes for lithium treatment that are enriched in the muscarinic acetylcholine receptors (mAChRs) 1 and 3 and the metabotropic glutamate receptor group III signaling pathways – well characterized biological pathways modulated by the most abundant neurotransmitters in the brain (glutamate and acetylcholine).

Acetylcholine is the central regulator of the mAChRs signaling pathways, which are subfamily of G protein-coupled receptor complexes located in the cell membranes of neurons and other cells that regulate fundamental functions of the central and peripheral nervous system including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibers in the parasympathetic nervous system<sup>32</sup>. The muscarinic antagonist scopolamine has antidepressant activity, while physostigmine, a cholinesterase inhibitor induces depressive symptoms, suggesting muscarinic receptors may play a role, not only in the pathogenesis of mood disorders, but also as therapeutic targets<sup>33</sup>. M1 and 3 receptors are localized in the cortex, hippocampus and substantia nigra and are known to activate protein kinase C (PKC), causing post-synaptic excitation. PKC is thought to be central in the molecular pathogenesis of BD.

Glutamate, the primary excitatory neurotransmitter in the central nervous system (CNS), exerts neuromodulatory actions via the activation of metabotropic glutamate (mGlu), a type of glutamate receptor that modulates synaptic transmission and neuronal excitability throughout the central nervous system<sup>34</sup>. Group III metabotropic glutamate receptors are largely presynaptically localized and downregulate neurotransmitter release from presynaptic terminals directly or indirectly. These receptors have a prominent expression in the brain, especially in the region of the hippocampus, and can lead to the inhibition of the cAMP cascade which is critical for the maintenance of long-term synaptic plasticity<sup>35</sup>. Growing evidence indicates that abnormalities in the glutamatergic system are implicated in the pathogenesis and treatment of mental health disorders<sup>36</sup> including BD<sup>37,38</sup>, SCZ<sup>39</sup>, neurodevelopmental disorders<sup>40</sup>, Huntington's disease<sup>41</sup> and Alzheimer's disease<sup>42</sup>. Studies have reported SNPs of the

mGluRs system associated with BD <sup>43</sup>, and in animal studies, lithium was found to alter intracellular calcium by modulating the activity of the metabotropic glutamatergic receptor system <sup>44</sup>. To summarise, findings from the genome-wide SNP association, gene-based and functional analysis highlight the possibility that mechanisms involving glutamate and acetylcholine signaling pathways might influence the therapeutic effects of lithium in patients with BD. Modulation of these pathways through genetic variants may disrupt or enhance lithium's clinical effectiveness.

Our study has some limitations. First, while our findings were replicated in an independent small size sample, the fact that it was replicated in the binary outcome, but not in the continuous outcome indicates the need for a larger replication cohort. Second, because  $\text{Li}^+_{\text{PGS}}$  was developed and evaluated in European-ancestry populations, the findings should be replicated in a multi-ethnic population to gauge generalizability. Furthermore, the risks and benefits of predictive models consisting of  $\text{Li}^+_{\text{PGS}}$  should be evaluated in prospective studies. Third,  $\text{Li}^+_{\text{PGS}}$  only explains about 2% of response variance in our cohort, and as such is comparable to PGSs from other phenotypes (SCZ, MDD) that have shown an association with treatment outcomes. On their own, these PGSs are not suited to clinical pharmacogenomic testing as they would not predict treatment response prospectively in individual patients. Prediction models combining  $\text{Li}^+_{\text{PGS}}$  with other PGSs <sup>13, 14</sup> and clinical characteristics <sup>19, 45</sup> may improve the clinical utility of PGSs. Such models would then need to be tested in prospective studies and clinical trials. Fourth, studies have shown that approaches to phenotyping of lithium treatment response can be improved using advanced methods such as machine learning <sup>46</sup>. Employing a more precise phenotype definition may result in the identification of novel candidate genes implicated in lithium treatment response and ultimately the development of more informative  $\text{Li}^+_{\text{PGS}}$ .

In conclusion, we developed a unique lithium treatment response polygenic score ( $\text{Li}^+_{\text{PGS}}$ ) that showed a positive association with better lithium treatment response in patients with BD. Our gene-based and functional analyses build upon the findings from existing molecular studies by linking lithium treatment response with muscarinic acetylcholine receptor signaling and metabotropic glutamate receptor pathways. Further pharmacological evaluation of these pathways in the context of BD and mood stabilizing treatments may prove fruitful.

## Abbreviations

ConLi<sup>+</sup>Gen

the International Consortium on Lithium Genetics, ALDA = Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder scale, HRC = Haplotype Reference Consortium (HRC), SNPs = Single Nucleotide Polymorphisms, MAF = Minor Allele Frequency, GWAS = Genome Wide Association analysis,  $\text{Li}^+_{\text{PGS}}$ =polygenic score for lithium treatment response, LOG = Leave-one-group out procedure

PsyCourse

Pathomechanisms and Signature in the Longitudinal Course of Psychosis study and BipoLife = German research consortium for the study of bipolar disorder.

## Declarations

## Declarations

### Declaration of interest

Eduard Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farindustria, Ferrer, Forest Research Institute, Gedeon Richter, GlaxoSmith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), and the Stanley Medical Research Institute. Michael Bauer has received grants from the Deutsche Forschungsgemeinschaft (DFG), and Bundesministeriums für Bildung und Forschung (BMBF), and served as consultant, advisor or CME speaker for the following entities: Allergan, Aristo, Janssen, Lilly, Lundbeck, neuraxpharm, Otsuka, Sandoz, Servier and Sunovion outside the submitted work. Sarah Kittel-Schneider has received grants and served as consultant, advisor or speaker for the following entities: Medice Arzneimittel Pütter GmbH and Shire/Takeda. Bernhard Baune has received grants and served as consultant, advisor or CME speaker for the following entities: AstraZeneca, Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Servier, the National Health and Medical Research Council, the Fay Fuller Foundation, the James and Diana Ramsay Foundation. Scott Clark has received grants and served as consultant, advisor or CME speaker for the following entities: Otsuka Australia, Lundbeck Australia, Janssen-Cilag Australia, Servier Australia. Tadafumi Kato received honoraria for lectures, manuscripts, and/or consultancy, from Kyowa Hakko Kirin Co, Ltd, Eli Lilly Japan K.K., Otsuka Pharmaceutical Co, Ltd, GlaxoSmithKline K.K., Taisho Toyama Pharmaceutical Co, Ltd, Dainippon Sumitomo Pharma Co, Ltd, Meiji Seika Pharma Co, Ltd, Pfizer Japan Inc., Mochida Pharmaceutical Co, Ltd, Shionogi & Co, Ltd, Janssen Pharmaceutical K.K., Janssen Asia Pacific, Yoshitomiyakuhin, Astellas Pharma Inc, Wako Pure Chemical Industries, Ltd, Wiley Publishing Japan, Nippon Boehringer Ingelheim Co Ltd, Kanae Foundation for the Promotion of Medical Science, MSD K.K., Kyowa Pharmaceutical Industry Co, Ltd and Takeda Pharmaceutical Co, Ltd. Tadafumi Kato also received a research grant from Takeda Pharmaceutical Co, Ltd. Peter Falkai has received grants and served as consultant, advisor or CME speaker for the following entities Abbott, GlaxoSmithKline, Janssen, Essex, Lundbeck, Otsuka, Gedeon Richter, Servier and Takeda as well as the German Ministry of Science and the German Ministry of Health. Eva Reininghaus has received grants and served as consultant, advisor or CME speaker for the following entities: Janssen and Institut Allergosan. Mikael Landén declares that, over the past 36 months, he has received lecture honoraria from Lundbeck and served as a scientific consultant for EPID Research Oy; no other equity ownership, profit-sharing agreements, royalties or patent. Kazufumi Akiyama has received consulting honoraria from Taisho Toyama Pharmaceutical Co, Ltd. In 2021, Jörg Zimmermann served as an advisor for Biogen concerning Aducanumab (Alzheimer's Disease). The other authors have no other conflict of interest to disclose.

# Declarations

## Abbreviations

OR = odds ratio, CI = Confidence interval,  $Li^+_{PGS}$  = polygenic score for lithium treatment response.

## Funding

Azmeraw T. Amare is supported by the 2019–2021 National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Grant from the Brain & Behaviour Research Foundation (BBRF) and National Health and Medical Research Council (NHMRC) Emerging Leadership Investigator Grant 2021–2008000. The primary sources of funding were the Deutsche Forschungsgemeinschaft (DFG; grant no. RI 908/7 – 1; grant FOR2107, RI 908/11 – 1 to Marcella Rietschel, NO 246/10 – 1 to Markus M. Nöthen) and the Intramural Research Program of the National Institute of Mental Health (ZIA-MH00284311; ClinicalTrials.gov identifier: NCT00001174). The genotyping was in part funded by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the e:Med Programme (grants awarded to Thomas G. Schulze, Marcella Rietschel, and Markus M. Nöthen). Improving Recognition and Care in Critical Areas of Bipolar Disorders (BipoLife) study was funded by Bundesministerium für Bildung und Forschung (BMBF): Pls – Felix BERPohl, Philipp Ritter, Michael Bauer, Andreas Reif, Sarah Kittel-Schneider, Thomas G. Schulze, Jens Wiltfang, Georg Juckel, Andreas Fallgatter and Martin Lambert. Urs Heilbronner was supported by European Union's Horizon 2020 Research and Innovation Programme (PSY-PGx, grant agreement No 945151). Some data and biomaterials were collected as part of eleven projects (Study 40) that participated in the National Institute of Mental Health (NIMH) Bipolar Disorder Genetics Initiative. From 2003–2007, the Principal Investigators and Co-Investigators were: Indiana University, Indianapolis, IN, R01 MH59545, John Nurnberger, M.D., Ph.D., Marvin J. Miller, M.D., Elizabeth S. Bowman, M.D., N. Leela Rau, M.D., P. Ryan Moe, M.D., Nalini Samavedy, M.D., Rif El-Mallakh, M.D. (at University of Louisville), Husseini Manji, M.D. (at Johnson and Johnson), Debra A. Glitz, M.D. (at Wayne State University), Eric T. Meyer, Ph.D., M.S. (at Oxford University, UK), Carrie Smiley, R.N., Tatiana Foroud, Ph.D., Leah Flury, M.S., Danielle M. Dick, Ph.D. (at Virginia Commonwealth University), Howard Edenberg, Ph.D.; Washington University, St. Louis, MO, R01 MH059534, John Rice, Ph.D., Theodore Reich, M.D., Allison Goate, Ph.D., Laura Bierut, M.D. K02 DA21237; Johns Hopkins University, Baltimore, M.D., R01 MH59533, Melvin McInnis, M.D., J. Raymond DePaulo, Jr., M.D., Dean F. MacKinnon, M.D., Francis M. Mondimore, M.D., James B. Potash, M.D., Peter P. Zandi, Ph.D., Dimitrios Avramopoulos, and Jennifer Payne; University of Pennsylvania, PA, R01 MH59553, Wade Berrettini, M.D., Ph.D.; University of California at San Francisco, CA, R01 MH60068, William Byerley, M.D., and Sophia Vinogradov, M.D.; University of Iowa, IA, R01 MH059548, William Coryell, M.D., and Raymond Crowe, M.D.; University of Chicago, IL, R01 MH59535, Elliot Gershon, M.D., Judith Badner, Ph.D., Francis McMahon, M.D., Chunyu Liu, Ph.D., Alan Sanders, M.D., Maria Caserta, Steven Dinwiddie, M.D., Tu Nguyen, Donna Harakal; University of California at San Diego, CA, R01 MH59567, John Kelsoe, M.D., Rebecca

McKinney, B.A.; Rush University, IL, R01 MH059556, William Scheftner, M.D., Howard M. Kravitz, D.O., M.P.H., Diana Marta, B.S., Annette Vaughn-Brown, M.S.N., R.N., and Laurie Bederow, M.A.; NIMH Intramural Research Program, Bethesda, MD, 1Z01MH002810-01, Francis J. McMahon, M.D., Layla Kassem, Psy.D., Sevilla Detera-Wadleigh, Ph.D, Lisa Austin, Ph.D, Dennis L. Murphy, M.D. ; Howard University, William B. Lawson, M.D., Ph.D., Evarista Nwulia, M.D., and Maria Hipolito, M.D. This work was supported by the NIH grants P50CA89392 from the National Cancer Institute and 5K02DA021237 from the National Institute of Drug Abuse.

## Acknowledgment

The authors are grateful to all patients who participated in the study and we appreciate the contributions of clinicians, scientists, research assistants and study staff who helped in the patient recruitment, data collection and biological sample preparation of the studies. We are also indebted to the members of the ConLi+Gen Scientific Advisory Board (<http://www.ConLi+Gen.org/>) for critical input over the course of the project.

## References

1. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. *Lancet* 2016; **387**(10027): 1561-1572.
2. DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**(10159): 1859-1922.
3. Walker S, Mackay E, Barnett P, Sheridan Rains L, Leverton M, Dalton-Locke C *et al.* Clinical and social factors associated with increased risk for involuntary psychiatric hospitalisation: a systematic review, meta-analysis, and narrative synthesis. *Lancet Psychiatry* 2019; **6**(12): 1039-1053.
4. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. *World Psychiatry* 2014; **13**(2): 153-160.
5. Cade JF. Lithium salts in the treatment of psychotic excitement. *The Medical journal of Australia* 1949; **2**(10): 349-352.
6. Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P *et al.* The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *The Australian and New Zealand journal of psychiatry* 2021; **55**(1): 7-117.
7. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A *et al.* Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. *Journal of psychopharmacology (Oxford, England)* 2016; **30**(6): 495-553.
8. Garnham J, Munro A, Slaney C, Macdougall M, Passmore M, Duffy A *et al.* Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. *Journal of affective disorders*


- 2007; **104**(1-3): 185-190.
9. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. *BMJ (Clinical research ed)* 2013; **346**: f3646.
  10. Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N *et al.* Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. *Lancet* 2016; **387**(10023): 1085-1093.
  11. Amare AT, Schubert KO, Baune BT. Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry. *EPMA J* 2017; **8**(3): 211-227.
  12. Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M *et al.* Is response to prophylactic lithium a familial trait? *The Journal of clinical psychiatry* 2002; **63**(10): 942-947.
  13. Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Cearns M *et al.* Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. *Mol Psychiatry* 2021; **26**(6): 2457-2470.
  14. International Consortium on Lithium G, Amare AT, Schubert KO, Hou L, Clark SR, Papiol S *et al.* Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. *JAMA Psychiatry* 2018; **75**(1): 65-74.
  15. Schubert KO, Thalamuthu A, Amare AT, Frank J, Streit F, Adl M *et al.* Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. *Transl Psychiatry* 2021; **11**(1): 606.
  16. Le Clerc S, Lombardi L, Baune BT, Amare AT, Schubert KO, Hou L *et al.* HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders. *Sci Rep* 2021; **11**(1): 17823.
  17. Chen CH, Lee CS, Lee MT, Ouyang WC, Chen CC, Chong MY *et al.* Variant GADL1 and response to lithium therapy in bipolar I disorder. *N Engl J Med* 2014; **370**(2): 119-128.
  18. Stacey D, Schubert KO, Clark SR, Amare AT, Milanese E, Maj C *et al.* A gene co-expression module implicating the mitochondrial electron transport chain is associated with long-term response to lithium treatment in bipolar affective disorder. *Transl Psychiatry* 2018; **8**(1): 183.
  19. Cearns M, Amare AT, Schubert KO, Thalamuthu A, Frank J, Streit F *et al.* Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach. *The British Journal of Psychiatry* 2022; **220**(4): 219-228.
  20. Manchia M, Adli M, Akula N, Arda R, Aubry JM, Backlund L *et al.* Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. *PLoS One* 2013; **8**(6): e65636.
  21. Dwyer DB, Kalman JL, Budde M, Kambeitz J, Ruef A, Antonucci LA *et al.* An Investigation of Psychosis Subgroups With Prognostic Validation and Exploration of Genetic Underpinnings: The PsyCourse Study. *JAMA Psychiatry* 2020; **77**(5): 523-533.

22. Ritter PS, Bermpohl F, Gruber O, Hautzinger M, Jansen A, Juckel G *et al.* Aims and structure of the German Research Consortium BipoLife for the study of bipolar disorder. *Int J Bipolar Disord* 2016; **4**(1): 26.
23. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *American journal of human genetics* 2007; **81**(3): 559-575.
24. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A *et al.* Next-generation genotype imputation service and methods. *Nat Genet* 2016; **48**(10): 1284-1287.
25. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* 2016; **48**(10): 1279-1283.
26. Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nature communications* 2019; **10**(1): 1776.
27. Southam L, Gilly A, Suveges D, Farmaki AE, Schwartzentruber J, Tachmazidou I *et al.* Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits. *Nature communications* 2017; **8**: 15606.
28. Sakaue S, Kanai M, Karjalainen J, Akiyama M, Kurki M, Matoba N *et al.* Trans-biobank analysis with 676,000 individuals elucidates the association of polygenic risk scores of complex traits with human lifespan. *Nat Med* 2020; **26**(4): 542-548.
29. Yee TW. The VGAM Package for Categorical Data Analysis. *Journal of Statistical Software* 2010; **32**(10): 1-34.
30. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput Biol* 2015; **11**(4): e1004219.
31. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R *et al.* PANTHER: a library of protein families and subfamilies indexed by function. *Genome Res* 2003; **13**(9): 2129-2141.
32. Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, Wess J. Muscarinic acetylcholine receptors: novel opportunities for drug development. *Nat Rev Drug Discov* 2014; **13**(7): 549-560.
33. Bymaster FP, Felder CC. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. *Mol Psychiatry* 2002; **7 Suppl 1**(1): S57-63.
34. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. *Annu Rev Pharmacol Toxicol* 2010; **50**: 295-322.
35. Mercier MS, Lodge D. Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential. *Neurochem Res* 2014; **39**(10): 1876-1894.
36. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. *Nat Rev Drug Discov* 2008; **7**(5): 426-437.
37. Matosin N, Fernandez-Enright F, Frank E, Deng C, Wong J, Huang XF *et al.* Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and



- nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. *J Psychiatry Neurosci* 2014; **39**(6): 407-416.
38. Itokawa M, Yamada K, Iwayama-Shigeno Y, Ishitsuka Y, Detera-Wadleigh S, Yoshikawa T. Genetic analysis of a functional GRIN2A promoter (GT)<sub>n</sub> repeat in bipolar disorder pedigrees in humans. *Neurosci Lett* 2003; **345**(1): 53-56.
  39. Tang J, Chen X, Xu X, Wu R, Zhao J, Hu Z *et al*. Significant linkage and association between a functional (GT)<sub>n</sub> polymorphism in promoter of the N-methyl-D-aspartate receptor subunit gene (GRIN2A) and schizophrenia. *Neurosci Lett* 2006; **409**(1): 80-82.
  40. Ende S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I *et al*. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. *Nat Genet* 2010; **42**(11): 1021-1026.
  41. Arning L, Kraus PH, Valentin S, Saft C, Andrich J, Epplen JT. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. *Neurogenetics* 2005; **6**(1): 25-28.
  42. Leuba G, Vernay A, Kraftsik R, Tardif E, Riederer BM, Savioz A. Pathological reorganization of NMDA receptors subunits and postsynaptic protein PSD-95 distribution in Alzheimer's disease. *Curr Alzheimer Res* 2014; **11**(1): 86-96.
  43. Blacker CJ, Lewis CP, Frye MA, Veldic M. Metabotropic glutamate receptors as emerging research targets in bipolar disorder. *Psychiatry Res* 2017; **257**: 327-337.
  44. Khayachi A, Ase A, Liao C, Kamesh A, Kuhlmann N, Schorova L *et al*. Chronic lithium treatment alters the excitatory/ inhibitory balance of synaptic networks and reduces mGluR5-PKC signalling in mouse cortical neurons. *J Psychiatry Neurosci* 2021; **46**(3): E402-E414.

## Figures



**Figure 1**

Overview of input datasets and steps of data analyses.

**Legend:** ConLi+Gen = the International Consortium on Lithium Genetics, ALDA = Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder scale, HRC= Haplotype Reference Consortium (HRC), SNPs = Single Nucleotide Polymorphisms, MAF=Minor Allele Frequency, GWAS = Genome Wide Association analysis,  $Li^+_{PGS}$  = polygenic score for lithium treatment response,

LOG=Leave-one-group out procedure; PsyCourse = Pathomechanisms and Signature in the Longitudinal Course of Psychosis study and BipoLife = German research consortium for the study of bipolar disorder.





Figure 2

Trends in the odds ratios (ORs) for favourable treatment response to lithium for patients with bipolar disorder in the higher genetic loading for lithium responsive variants, deciles (2<sup>nd</sup> to 10<sup>th</sup>) compared with patients in the lowest (decile 1<sup>st</sup>) of genetic loading for lithium response (n = 2,367).

**Legend:** The X mark on the line plot indicates that the association is not statistically significant at that decile.

**Abbreviations:** OR= odds ratio, CI=Confidence interval, Li<sup>+</sup> PGS =polygenic score for lithium treatment response.



**Figure 3**

Manhattan plots showing the SNP-based GWAS results of lithium treatment response in patients with bipolar disorder; A) in the categorical outcome and B) continuous scale, highlighting the loci that showed genome-wide significance (orange).

**Legend:** The  $-\log_{10}$  (p-value) is plotted against the physical position of each SNP on each chromosome. The threshold for genome-wide significance (p-value  $< 5 \times 10^{-8}$ ) is indicated by the red dotted horizontal line

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigureandTable.docx](#)